Vertex Pharmaceuticals (VRTX)

Sector:Health Care
Super Investor Stats:
Ownership count:3
Ownership rank:206
% of all portfolios:0.041%
Hold Price * :$465.06
History Portfolio Manager Activity Share change % change to portfolio
Q3  2024
Torray Funds Add 13.01% 1,813 0.12
John Armitage - Egerton Capital Buy 124,045 0.58
Q2  2024
Torray Funds Add 0.28% 39 0.00
Tweedy Browne Co. - Tweedy Browne Value Fund Reduce 16.96% 3,135 0.35
Q1  2024
Lee Ainslie - Maverick Capital Sell 100.00% 812 0.01
Torray Funds Reduce 1.20% 169 0.01
Q4  2023
Lee Ainslie - Maverick Capital Reduce 44.27% 645 0.01
Torray Funds Buy 14,068 0.93
Q3  2023
Lee Ainslie - Maverick Capital Buy 1,457 0.01
Tweedy Browne Co. - Tweedy Browne Value Fund Reduce 3.65% 700 0.06
Q2  2023
Tweedy Browne Co. - Tweedy Browne Value Fund Reduce 19.45% 4,635 0.39
Q4  2021
Lee Ainslie - Maverick Capital Sell 100.00% 18,052 0.04
Tweedy Browne Co. - Tweedy Browne Value Fund Buy 23,825 1.26
Q3  2021
Lee Ainslie - Maverick Capital Buy 18,052 0.04
Q2  2021
Lee Ainslie - Maverick Capital Sell 100.00% 6,254 0.01
Q1  2021
Lee Ainslie - Maverick Capital Buy 6,254 0.01
Q2  2020
Lee Ainslie - Maverick Capital Sell 100.00% 460 0.00
Q1  2020
Lee Ainslie - Maverick Capital Buy 460 0.00
Q2  2015
Lee Ainslie - Maverick Capital Sell 100.00% 524,867 1.00
Q1  2015
Lee Ainslie - Maverick Capital Buy 524,867 1.00
Q2  2009
Bill & Melinda Gates Foundation Trust Sell 100.00% 95,000 0.03
Q1  2009
Bill & Melinda Gates Foundation Trust Buy 95,000 0.03

* "Hold Price" is the last known price at which an investor still held a security. It is the closing price of the security as of the portfolio date (quarter end). This value is only provided when a security is owned by at least two investors. In the case of reporting dates being different, a weighted average price is calculated.